Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients
Hess U;Böhme C;Rey K;Senn HJ;;
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer1998Vol. 6pp. -
365
u1998supportivemonotherapy
Abstract
Between July 1993 and September 1996, 107 consecutive febrile episodes in 83 neutropenic cancer patients with a median age of 41 years were randomized to treatment either with piperacillin/tazobactam 4.5 g every 8 h i.v. or ceftazidime 2 g every 8 h plus amikacin 15 mg/kg i.v. per day. In the case o …